Significant Ownership of Sofinnova Venture Partners IX, L.P.
- Large-stake filing summary
-
- Recent SEC Schedule 13D/G filings for Sofinnova Venture Partners IX, L.P. focus on large-stake beneficial ownership disclosures and amendments.
- Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
- Manager signature
- /s/ Nathalie Auber - Nathalie Auber/Attorney-in-Fact
- Manager location
- Menlo Park, CA
Large-stake snapshot
1 signal
Manager
Names, identifiers, and filing context for this profile.
2 identity fields
Follow Filing Activity
Follow Sofinnova Venture Partners IX, L.P. with Pro and return when a new Schedule 13D/G filing changes the record on this page.
Pro alert delivery is coming soon and remains tied to source-backed filing changes rather than inferred market advice.
CIK context first
Continue from Sofinnova Venture Partners IX, L.P.
Significant Ownership of Sofinnova Venture Partners IX, L.P.
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| NXTC | NextCure, Inc. | Common Stock, $0.001 par value | 7.1% | $2,947,939 | 222,654 | Sofinnova Venture Partners IX, L.P. ("SVP IX") | 19 Dec 2025 | ||
| AVBP | ArriVent Biopharma, Inc. | Common Stock, $0.0001 Par Value per Share | 4.1% | $35,767,532 | 1,696,752 | Sofinnova Venture Partners XI, L.P. ("SVP XI") | 31 Dec 2025 |
Schedules 13D/G Reported by Sofinnova Venture Partners IX, L.P.:
| Sym | Target | Class | Ownership | Change | Current shares | Change | Value | Reporting name | Form | Report period | Filing date |
|---|
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.